Table 1.
Clinical and demographic data of investigated cohorts.
| Clinical and Demographic Data | ||
| Total N = 104 | ||
| Treatment-resistant cohort | N | 42 |
| age | 18·79 ± 8.3 SD 3 | |
| Gender | 74% male 4 | |
| Basal CGI | 6 ± 0.99 | |
| Basal CGAS | 30.02 ± 13.28 | |
| Control | N | 62 |
| age | 13.83 ± 3.8 | |
| Gender | 92% male | |
| Basal CGI | 4.33 ± 0.80 | |
| Basal CGAS | 44.32 ± 9 | |
| Medication | ||
| Treatment resistant | Control | |
| Antipsychotics 1 | 28 (67%) | 29 (32%) |
| Antidepressants 2 | 20 (48%) | 10 (11%) |
| Anxiolytics, anticonvulsants and others | 21 (26%) | 50 (56%) |
| No current medication | 3 (7%) | 0 |
1 Antipsychotic drugs used: risperidone (43%), aripiprazole (26%), olanzapine (14%), quetiapine (11%), paliperidone (6%). 2 Antidepressant drugs used: fluoxetine (39%), sertraline (26%), paroxetine (13%), fluvoxamine (3%), escitalopram (3%), duloxetine (9%), desvenlafaxine (6%). 3 The treatment-resistant cohort was relatively older than the control group (p = 0.001). 4 Gender distribution was not significantly different between cohorts (p = 0.10).